-Search query
-Search result
Showing 1 - 50 of 285 items for (author: wright & e)
EMDB-44965:
Sub-tomogram average of the RSV M lattice from native virions released from RSV-infected BEAS-2B cells cultured on EM grids
Method: subtomogram averaging / : Sibert BS, Wright ER
EMDB-44966:
Sub-tomogram average of a pair of RSV F trimers from native virions released from RSV-infected BEAS-2B cells cultured on EM grids
Method: subtomogram averaging / : Sibert BS, Wright ER
EMDB-44968:
Sub-tomogram average of two pairs of RSV F trimers from the surface of native virions released from RSV-infected BEAS-2B cells cultured on EM grids
Method: subtomogram averaging / : Sibert BS, Wright ER
EMDB-44969:
Sub-tomogram average of two pairs of RSV F trimers from the surface of native virions released from RSV-infected BEAS-2B cells cultured on EM grids
Method: subtomogram averaging / : Sibert BS, Wright ER
EMDB-44971:
Sub-tomogram average of two pairs of RSV F trimers from the surface of native virions released from RSV-infected BEAS-2B cells cultured on EM grids
Method: subtomogram averaging / : Sibert BS, Wright ER
EMDB-45639:
Cryo-EM structure of in-vitro alpha-synuclein fibril
Method: helical / : Sanchez JC, Borcik CG, Tonelli M, Sibert B, Rienstra CM, Wright ER, Cai K
PDB-9ck3:
Cryo-EM structure of in-vitro alpha-synuclein fibril
Method: helical / : Sanchez JC, Borcik CG, Tonelli M, Sibert B, Rienstra CM, Wright ER
EMDB-42770:
Caulobacter crescentus FljM flagellar filament (symmetrized)
Method: helical / : Sanchez JC, Montemayor EJ, Ploscariu NT, Parrell D, Baumgardt JK, Yang JE, Sibert B, Cai K, Wright ER
PDB-8uxn:
Caulobacter crescentus FljM flagellar filament (symmetrized)
Method: helical / : Sanchez JC, Montemayor EJ, Ploscariu NT, Parrell D, Baumgardt JK, Yang JE, Sibert B, Cai K, Wright ER
EMDB-42766:
Caulobacter crescentus FljK flagellar filament (asymmetrical)
Method: single particle / : Sanchez JC, Montemayor EJ, Ploscariu NT, Parrell D, Baumgardt JK, Yang JE, Sibert B, Cai K, Wright ER
PDB-8uxj:
Caulobacter crescentus FljK flagellar filament (asymmetrical)
Method: single particle / : Sanchez JC, Montemayor EJ, Ploscariu NT, Parrell D, Baumgardt JK, Yang JE, Sibert B, Cai K, Wright ER
EMDB-18051:
Inward-facing, closed proteoliposome complex I at 3.1 A. Initially purified in DDM.
Method: single particle / : Grba DN, Hirst J
EMDB-18052:
Inward-facing, open2 proteoliposome complex I at 3.1 A. Initially purified in DDM.
Method: single particle / : Grba DN, Hirst J
EMDB-18054:
Inward-facing, slack proteoliposome complex I at 3.1 A. Initially purified in DDM.
Method: single particle / : Grba DN, Hirst J
EMDB-18055:
Outward-facing, closed proteoliposome complex I at 3.1 A. Initially purified in DDM.
Method: single particle / : Grba DN, Hirst J
EMDB-18057:
Outward-facing, open2 proteoliposome complex I at 3.1 A. Initially purified in DDM.
Method: single particle / : Grba DN, Hirst J
EMDB-18059:
Outward-facing, slack proteoliposome complex I at 3.1 A. Initially purified in DDM.
Method: single particle / : Grba DN, Hirst J
EMDB-18066:
Inward-facing, open2 proteoliposome complex I at 2.9 A, after deactivation treatment. Initially purified in LMNG.
Method: single particle / : Grba DN, Hirst J
EMDB-18067:
Inward-facing, open1 proteoliposome complex I at 3.3 A, after deactivation treatment. Initially purified in LMNG.
Method: single particle / : Grba DN, Hirst J
EMDB-18068:
Outward-facing, open2 proteoliposome complex I at 2.6 A, after deactivation treatment. Initially purified in LMNG.
Method: single particle / : Grba DN, Hirst J
EMDB-18069:
Outward-facing, open1 proteoliposome complex I at 2.8 A, after deactivation treatment. Initially purified in LMNG.
Method: single particle / : Grba DN, Hirst J
EMDB-18138:
Inward-facing, closed proteoliposome complex I at 2.7 A. Initially purified in LMNG.
Method: single particle / : Grba DN, Hirst J
EMDB-18139:
Inward-facing, open2 proteoliposome complex I at 2.6 A. Initially purified in LMNG.
Method: single particle / : Grba DN, Hirst J
EMDB-18140:
Inward-facing, open1 proteoliposome complex I at 2.9 A. Initially purified in LMNG.
Method: single particle / : Grba DN, Hirst J
EMDB-18141:
Outward-facing, closed proteoliposome complex I at 2.5 A. Initially purified in LMNG.
Method: single particle / : Grba DN, Hirst J
EMDB-18142:
Outward-facing, open2 proteoliposome complex I at 2.6 A. Initially purified in LMNG.
Method: single particle / : Grba DN, Hirst J
EMDB-18143:
Outward-facing, open1 proteoliposome complex I at 2.6 A. Initially purified in LMNG.
Method: single particle / : Grba DN, Hirst J
PDB-8q0a:
Inward-facing, closed proteoliposome complex I at 3.1 A. Initially purified in DDM.
Method: single particle / : Grba DN, Hirst J
PDB-8q0f:
Inward-facing, open2 proteoliposome complex I at 3.1 A. Initially purified in DDM.
Method: single particle / : Grba DN, Hirst J
PDB-8q0j:
Inward-facing, slack proteoliposome complex I at 3.8 A. Initially purified in DDM.
Method: single particle / : Grba DN, Hirst J
PDB-8q0m:
Outward-facing, closed proteoliposome complex I at 3.1 A. Initially purified in DDM.
Method: single particle / : Grba DN, Hirst J
PDB-8q0o:
Outward-facing, open2 proteoliposome complex I at 3.1 A. Initially purified in DDM.
Method: single particle / : Grba DN, Hirst J
PDB-8q0q:
Outward-facing, slack proteoliposome complex I at 3.6 A. Initially purified in DDM
Method: single particle / : Grba DN, Hirst J
PDB-8q1p:
Inward-facing, open2 proteoliposome complex I at 2.9 A, after deactivation treatment. Initially purified in LMNG.
Method: single particle / : Grba DN, Hirst J
PDB-8q1u:
Inward-facing, open1 proteoliposome complex I at 3.3 A, after deactivation treatment. Initially purified in LMNG.
Method: single particle / : Grba DN, Hirst J
PDB-8q1y:
Outward-facing, open2 proteoliposome complex I at 2.6 A, after deactivation treatment. Initially purified in LMNG.
Method: single particle / : Grba DN, Hirst J
PDB-8q25:
Outward-facing, open1 proteoliposome complex I at 2.8 A, after deactivation treatment. Initially purified in LMNG.
Method: single particle / : Grba DN, Hirst J
PDB-8q45:
Inward-facing, closed proteoliposome complex I at 2.7 A. Initially purified in LMNG.
Method: single particle / : Grba DN, Hirst J
PDB-8q46:
Inward-facing, open2 proteoliposome complex I at 2.6 A. Initially purified in LMNG.
Method: single particle / : Grba DN, Hirst J
PDB-8q47:
Inward-facing, open1 proteoliposome complex I at 2.9 A. Initially purified in LMNG.
Method: single particle / : Grba DN, Hirst J
PDB-8q48:
Outward-facing, closed proteoliposome complex I at 2.5 A. Initially purified in LMNG.
Method: single particle / : Grba DN, Hirst J
PDB-8q49:
Outward-facing, open2 proteoliposome complex I at 2.6 A. Initially purified in LMNG.
Method: single particle / : Grba DN, Hirst J
PDB-8q4a:
Outward-facing, open1 proteoliposome complex I at 2.6 A. Initially purified in LMNG.
Method: single particle / : Grba DN, Hirst J
EMDB-18639:
Locally refined SARS-CoV-2 BA-2.86 Spike receptor binding domain (RBD) complexed with angiotensin converting enzyme 2 (ACE2)
Method: single particle / : Ren J, Stuart DI, Duyvesteyn HME
EMDB-18649:
Local refinement of SARS-CoV-2 BA.2.86 Spike and XBB-7 Fab
Method: single particle / : Ren J, Duyvesteyn HME, Stuart DI
EMDB-19002:
XBB-4 Fab in complex with SARS-CoV-2 BA.2.12.1 Spike Glycoprotein
Method: single particle / : Duyvesteyn HME, Ren J, Stuart DI
PDB-8qsq:
Locally refined SARS-CoV-2 BA-2.86 Spike receptor binding domain (RBD) complexed with angiotensin converting enzyme 2 (ACE2)
Method: single particle / : Ren J, Stuart DI, Duyvesteyn HME
PDB-8qtd:
Local refinement of SARS-CoV-2 BA.2.86 Spike and XBB-7 Fab
Method: single particle / : Ren J, Duyvesteyn HME, Stuart DI
PDB-8r8k:
XBB-4 Fab in complex with SARS-CoV-2 BA.2.12.1 Spike Glycoprotein
Method: single particle / : Duyvesteyn HME, Ren J, Stuart DI
Pages: